Skip to main content
SpringerLink
Log in

Adhesion-GPCRs in Tumorigenesis

  • Chapter
Adhesion-GPCRs

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 706))

Abstract

Tumor growth is a highly complex, multistep process that involves tumor cell detachment, migration, invasion and metastasis accompanied by angiogenesis and extracellular matrix turn-over. Each of the steps is influenced by tumor cell interaction and interaction of the tumor cell with its microenvironment that consists of different cell types as tumor-associated fibroblasts, endothelial cells and leukocytes as well as the extracellular matrix produced by the tumor cells themselves or by the fibroblasts.

Cellular communication takes place by the regulated expression of adhesion receptors. Adhesion-GPCRs are characterized by very long extracellular N-termini that have multiple domains. When considering this complex structure it is only logical that adhesion-GPCRs are involved in tumor cell interactions. Moreover, these receptors function in cell guidance and/or trafficking, which, in addition to their structure, makes them interesting for tumorigenesis.

The aberrant expression of several adhesion-GPCRs on tumor cells and their involvement in tumor growth have been shown for some of the family members. This overview summarizes expression database data as well as data from original research articles of adhesion-GPCRs in tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. BioGPS; http://biogps.gnf; 2009.

  2. Human Protein Atlas (HPA); http://www.proteinatlas.org; 2009.

  3. Atlas of Genetics and Cytogenetics in Oncology and Haematology (AGCOH); http://atlasgeneticsoncology.org; 2009.

  4. Bjarnadottir TK, Fredriksson R, Schioth HB. The adhesion-GPCRs: a unique family of G protein-coupled receptors with important roles in both central and peripheral tissues. Cell Mol Life Sci 2007; 64:2104–2119.

    Article  PubMed  CAS  Google Scholar 

  5. Ichtchenko K, Bittner MA, Krasnoperov V et al. A novel ubiquitously expressed alpha-latrotoxin receptor is a member of the CIRL family of G-protein-coupled receptors. J Biol Chem 1999; 274:5491–5498.

    Article  PubMed  CAS  Google Scholar 

  6. Matsushita H, Lelianova VG, Ushkaryov YA. The latrophilin family: multiply spliced G protein-coupled receptors with differential tissue distribution. FEBS Lett 1999; 443:348–352.

    Article  PubMed  CAS  Google Scholar 

  7. Sudhof TC. Alpha-latrotoxin and its receptors: neurexins and CIRL/latrophilins. Annu Rev Neurosci 2001; 24:933–962.

    Article  PubMed  CAS  Google Scholar 

  8. White GR, Varley JM, Heighway J. Isolation and characterization of a human homologue of the latrophilin gene from a region of 1p31.1 implicated in breast cancer. Oncogene 1998; 17:3513–3519.

    Article  PubMed  CAS  Google Scholar 

  9. White GR, Varley JM, Heighway J. Genomic structure and expression profile of LPHH1, a 7TM gene variably expressed in breast cancer cell lines. Biochim Biophys Acta 2000; 1491:75–92.

    PubMed  CAS  Google Scholar 

  10. Jaspars LH, Vos W, Aust G et al. Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens 2001; 57:325–331.

    Article  PubMed  CAS  Google Scholar 

  11. Aust G, Wandel E, Boltze C et al. Diversity of CD97 in smooth muscle cells (SMCs). Cell Tissue Res 2006;323:1–9.

    Article  Google Scholar 

  12. Wobus M, Vogel B, Schmücking E et al. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer 2004; 112:815–822.

    Article  PubMed  CAS  Google Scholar 

  13. Aust G. Immunohistochemical detection of CD97 in colorectal carcinomas. In: Hayat MA, ed. Immunohistochemistry and in situ hybridization of human carcinomas. Burlington, San Diego, London: Elsevier Academic Press, 2005:201–206.

    Google Scholar 

  14. Aust G, Eichler W, Laue S et al. CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res 1997; 57:1798–1806.

    PubMed  CAS  Google Scholar 

  15. Boltze C, Schneider-Stock R, Aust G et al. CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol Int 2002; 52:83–88.

    Article  PubMed  CAS  Google Scholar 

  16. Hamann J, Vogel B, van Schijndel GM et al. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996; 184:1185–1189.

    Article  PubMed  CAS  Google Scholar 

  17. Hoang-Vu C, Bull K, Schwarz I et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:1104–1109.

    Article  PubMed  CAS  Google Scholar 

  18. Steinert M, Wobus M, Boltze C et al. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol 2002; 161:1657–1667.

    Article  PubMed  CAS  Google Scholar 

  19. Aust G, Steinert M, Schütz A et al. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic and esophageal carcinomas. Am J Clin Pathol 2002; 118:699–707.

    Article  PubMed  CAS  Google Scholar 

  20. Galle J, Sittig D, Hanisch I et al. Individual cell—based models of tumor—environment interactions. Multiple effects of CD97 on tumor invasion. Am J Pathol 2006; 169:1802–1811.

    Article  PubMed  CAS  Google Scholar 

  21. Hamann J, Wishaupt JO, van Lier RA et al. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum 1999; 42:650–658.

    Article  PubMed  CAS  Google Scholar 

  22. Wang T, Ward Y, Tian L et al. CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counter receptors on endothelial cells. Blood 2004; 105:2836–2844.

    Article  PubMed  Google Scholar 

  23. Aust G, Hamann J, Schilling N et al. Detection of alternatively spliced EMR2 mRNAs in colorectal tumor cell lines but rare expression of the molecule in the corresponding adenocarcinomas. Virchows Arch 2003; 443:32–37.

    Article  PubMed  CAS  Google Scholar 

  24. Lin HH, Stacey M, Hamann J et al. Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97. Genomics 2000; 67:188-200.

    Google Scholar 

  25. Lagerstrom MC, Rabe N, Haitina T et al. The evolutionary history and tissue mapping of GPR123: specific CNS expression pattern predominantly in thalamic nuclei and regions containing large pyramidal cells. J Neurochem 2007; 100:1129–1142.

    Article  PubMed  Google Scholar 

  26. Carson-Walter EB, Watkins DN, Nanda A et al. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61:6649–6655.

    PubMed  CAS  Google Scholar 

  27. Vallon M, Essler M. Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans. J Biol Chem 2006; 281:34179–34188.

    Article  PubMed  CAS  Google Scholar 

  28. Pickering C, Hagglund M, Szmydynger-Chodobska J et al. The Adhesion GPCR GPR125 is specifically expressed in the choroid plexus and is upregulated following brain injury. BMC Neurosci 2008; 9:97.

    Article  PubMed  Google Scholar 

  29. Katoh M, Katoh M. Comparative integromics on noncanonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells. Int J Mol Med 2007; 20:405–409.

    PubMed  CAS  Google Scholar 

  30. Kaur B, Brat DJ, Calkins CC et al. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003; 162:19–27.

    Article  PubMed  CAS  Google Scholar 

  31. Kee HJ, Ahn KY, Choi KC et al. Expression of brain-specific angiogenesis inhibitor 3 (BAI3) in normal brain and implications for BAI3 in ischemia-induced brain angiogenesis and malignant glioma. FEBS Lett 2004; 569:307–316.

    Article  PubMed  CAS  Google Scholar 

  32. Mori K, Kanemura Y, Fujikawa H et al. Brain-specific angiogenesis inhibitor 1 (BAI1) is expressed in human cerebral neuronal cells. Neurosci Res 2002; 43:69–74.

    Article  PubMed  CAS  Google Scholar 

  33. Nishimori H, Shiratsuchi T, Urano T et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997; 15:2145–2150.

    Article  PubMed  CAS  Google Scholar 

  34. Koh JT, Kook H, Kee HJ et al. Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin. Exp Cell Res 2004; 294:172–184.

    Article  PubMed  CAS  Google Scholar 

  35. Kaur B, Brat DJ, Devi NS et al. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005; 24:3632–3642.

    Article  PubMed  CAS  Google Scholar 

  36. Kudo S, Konda R, Obara W et al. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep 2007; 18:785–791.

    PubMed  CAS  Google Scholar 

  37. Kang X, Xiao X, Harata M et al. K. Antiangiogenic activity of BAI1 in vivo: implications for gene therapy of human glioblastomas. Cancer Gene Ther 2006; 13:385–392.

    Article  PubMed  CAS  Google Scholar 

  38. Zendman AJ, Comelissen IM, Weidle UH et al. TM7XN1, a novel human EGF-TM7-like cDNA, detected with mRNA differential display using human melanoma cell lines with different metastatic potential. FEBS Lett 1999; 446:292–298.

    Article  PubMed  CAS  Google Scholar 

  39. Jin Z, Tietjen I, Bu L et al. Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. Hum Mol Genet 2007; 16:1972–1985.

    Article  PubMed  CAS  Google Scholar 

  40. Piao X, Hill RS, Bodell A et al. G protein-coupled receptor-dependent development of human frontal cortex. Science 2004; 303:2033–2036.

    Article  PubMed  CAS  Google Scholar 

  41. Huang Y, Fan J, Yang J et al. Characterization of GPR56 protein and its suppressed expression in human pancreatic cancer cells. Mol Cell Biochem 2008; 308:133–139.

    Article  PubMed  CAS  Google Scholar 

  42. Xu L, Begum S, Hearn JD et al. GPR56, an atypical G protein-coupled receptor, binds tissue transglutaminase, TG2 and inhibits melanoma tumor growth and metastasis. Proc Natl Acad Sci USA 2006; 103:9023–9028.

    Article  PubMed  CAS  Google Scholar 

  43. Xu, L, Hynes Ro. GPR56 and TgG2 possible roles in suppression of tumor growth by the microenvironment. Cell Cycle 2007; 6:760–765.

    Google Scholar 

  44. Jones RA, Kotsakis P, Johnson TS et al. Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth. Cell Death Differ 2006; 13:1442–1453.

    Article  PubMed  CAS  Google Scholar 

  45. Shashidhar S, Lorente G, Nagavarapu U et al. GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion. Oncogene 2005; 24:1673–1682.

    Article  PubMed  CAS  Google Scholar 

  46. Ke N, Sundaram R, Liu G et al. Orphan G protein-coupled receptor GPR56 plays a role in cell transformation and tumorigenesis involving the cell adhesion pathway. Mol Cancer Ther 2007; 6:1840–1850.

    Article  PubMed  CAS  Google Scholar 

  47. Kim JE, Han JM, Park CR et al. Splicing variants of the orphan G-protein-coupled receptor GPR56 regulate the activity of transcription factors associated with tumorigenesis. J Cancer Res Clin Oncol 2009.

    Google Scholar 

  48. Obermann H, Samalecos A, Osterhoff C et al. HE6, a two-subunit heptahelical receptor associated with apical membranes of efferent and epididymal duct epithelia. Mol Reprod Dev 2003; 64:13–26.

    Article  PubMed  CAS  Google Scholar 

  49. Fredriksson R, Lagerstrom MC, Hoglund PJ et al. Novel human G protein-coupled receptors with long N-terminals containing GPS domains and Ser/Thr-rich regions. FEBS Lett 2002; 531:407–414.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine; Department of Surgery, Research Laboratories, University of Leipzig, Liebigstr. 20, D-04103, Leipzig, Germany

    Gabriela Aust

Authors
  1. Gabriela Aust
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel

    Simon Yona PhD

  2. Institute of Molecular and Cellular Biology, University of Leeds, Leeds, UK

    Martin Stacey DPhil

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Landes Bioscience and Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Aust, G. (2010). Adhesion-GPCRs in Tumorigenesis. In: Yona, S., Stacey, M. (eds) Adhesion-GPCRs. Advances in Experimental Medicine and Biology, vol 706. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-7913-1_9

Download citation

Publish with us

Policies and ethics

Search

Navigation